Jeff. thank everyone, and joining Good you you, morning, Thank for us today.
expanding programs, progress in diversifying We advancing, which several are of are stage in great late pipeline making development. our and
indications focused different with we number need orphan Jeff distinct with to ranging programs across unmet indication the and neuro to these X franchises X a rare different mentioned, the and launch now development under of assets ability registrational coming from have years. As XX high studies in preclinical on
think development can how over clinical is full grown much past has And I year. on you shown Our Slide X. it appreciate pipeline the
our appreciates had in of drugs. need of we encouraged on limitation program the the some discuss options and each sleep in for burden We discussions steps by next the by unmet me feel program. Let sectors. We start in FDA wake in our updates with disease, our off-label of agency treatment met agency were data, March use understands sharing We to high growth of the the IH franchise with current and and our Idiopathic Starting scheduled in IH. the Hypersomnia. the the the key
ongoing based is we supports extension pitolisant's While in data totality high, bar on the generated in we patients moving are including the the IH. second study the for data plan the of approval submit from from be strongly an XXXX. the efficacy half and to will study, which with of The understand sNDA long-term forward submission
included have in supportive We further identified other be also strengthen submission. will to that information sNDA the our
a optimistic and simple established scheduled, regimen. remain dosing living to We and new with bringing committed treatment in are that IH is patients a profile has safety option an not
pediatric Moving narcolepsy. to
PDUFA the for of are XX. We track date on June
We options pediatric for highlights the are approximately decision living to pleased with the narcolepsy. priority for review. treatment FDA's patients with need X,XXX This decision new the
TEMPO the we a will placebo global that first Phase For a quarter. randomized randomize study XXX study placebo-controlled III the development initiated or multicenter patients X:X is Prader-Willi ratio. Syndrome, in This in in double-blind approximately
are committed pediatric for obtaining to We exclusivity pitolisant.
We in PWS data PWS, are requirements: the the pediatric and sNDA patients, peds narcolepsy but study and in submitting in on X good progress making data III narcolepsy Phase initiating respectively.
pediatric exclusivity to longest of Hoping months the commercial represents patent, the for regulatory end X will and opportunity add significant exclusivity this WAKIX. back a of
other An to new element disorders. assets extending and XXXX generating improved wake with to market the beyond with is of of strategy goal new our based of franchise important new franchise people for narcolepsy growth the and the bringing IP, versions living pitolisant sleep pitolisant develop and pitolisant
formulations, NGX, and NextGen our partner,. NGX on We X, with these are good X, making NextGen progress
to designed to an designed as the beginning The the need pitolisant NGX important ability range range. side and of bioequivalence WAKIX decrease to positive compared to development dose We potentially have the an are that to in the data for is differentiation formulation rather to and upgraded WAKIX pleased enteric-coated also to formulation additional PK GI XX.X titrate pitolisant start demonstrate through report at therapeutic NGX pathway. up to than is effects dosing the milligram therapeutic clinical
will by dosing differentiation be clinical This optimization supported study. a
step Slide AUC year. include bioavailability. a PDUFA the showed expect for and on BE date and of X, rate next initiating fourth bioequivalence on demonstrating absorption similar shown NGX NGX dosing pilot in in XXXX. time this As the the relative is studies study the Cmax The development WAKIX, and pivotal that and of quarter between optimization extent line, we Based
In patent NGX the for protection and addition, our out patent provisional has to for XXXX. potential been filed
will deliver or optimized program a a development expected NGX. of profile Nex-Gen end to WAKIX is PK is and the on an a life trend. formulation cycle. to have enhanced X, to higher new an profit IP, pitolisant and formulation Moving This designed This towards launch full of
to are We this year. formulation first on in from report track the half this of PK data
continue licensing novel very for wake established TPMXXXX, and in step a orexin agonist. commercialization as current also best-in-class product are orexin TMXXXX with pleased both X it expertise, treatments and the development position profile and licensing in leverages strengthen receptor leadership to sleep experience us, of We agonist represents to for the receptor disorders. for steerage our potential of a our next amongst X
once It data its agonist chemical has to its a compared potential to new will scaffold focus preclinical profile sharing safety best-in-class daily The TMXXXX sleep-wake treatment the profile. contributing selectivity, good unique potentially the profile. X potential evaluated scientific of dosing We upcoming other potency, product an on forward preclinical look the high other its disorders. data based for be and orexin for at good to and conference. narcolepsy
studies XXXX. initiate in in first improvement development terms to In half and second of file we IND an milestones, expect mid-XXXX of
pharmaceutically a which our synthetic of with a be our asset disorder for THC the cell patent-protected nerve like devoid to growing franchise a cannabidiol on franchise. ZYNXXX, transdermal neurobehavioral with could manufactured, franchise. in delivery, next enhance Moving foundational
We are medical alone approved in III in syndrome. in is With currently X with Phase treatment, unmet patients the XX,XXX pivotal syndrome need. enrolling Fragile no U.S. significant diagnosed RECONNECT the patients there trial approximately and Fragile X
quarter top first data of the mid-XXXX. in line in enrollment patient complete to expect We XXXX with
opportunity alone FDA this Phase Deletion program like represents an approximately XX,XXX III and in to in in about the INSPIRE interacting in was patients This signals the with and with XXq with XXQ ZYNXXX abhorrent deletion been franchise. XXq Phase study, checklist. patients Syndrome also U.S. have study the we in help positive open-label and generated studied II expanding syndrome proof-of-concept another
this is a noting patients It X for to XXq Syndrome look bring exploring normal the Fragile opportunities around and is worth ZYNXXX opportunity syndrome world. treatment forward and we to living global Harmony, with Deletion to
orphan global neuro brings This of establishment of both targeting third our acquisition the us. in today opportunities assets with announced for great us Therapeutics. X epilepsy Epygenix the we rare Finally, acquisition franchise epilepsies,
currently potent, centrally in which high syndrome encephalopathy and need. a treatment the syndrome unmet first agonist, asset pivotal Dravet for epileptic EPX-XXX the of is children a serotonin acting clinical is registrational Dravet trial rare and severe with hydrochloride, clemizole is The developmental in medical adults.
study in from could data mechanism action schematic this efficacy, DS. study the with available study trial unmet the proven system another of anticipate good importantly, Lennox-Gastaut The anticipate and orphan for in to poised pediatric ARGUS registration disease the line rare product XXXX.
EPX-XXX medical enter top The starting for both for also trial as of second with and via syndrome, this We quality need. of seratonic encephlogathy high safer and a half design the currently is and and XX. the rare serious the syndrome the functioning designations than on Lennox-Gastaut of offer is of registrational life EPX-XXX study III clemizole FDA has patients and epileptic treatment options received profile syndrome. in Dravet the a XXXX. improve Phase both developmental from treatment shown Slide ARGUS drug known designation We of
for centrally that product, syndrome a Our selective and drug XTC received Lennox-Gastaut. Dravet EPX-XXX syndrome orphan agent is Lennox-Gastaut currently IND-enabling investigational designation studies. potent, for second also EPXXXX is in after acting designation
To conclude.
different all across We the these disorders could or year rare potential the tremendous resulting and new pipeline programs of X investigating. launch of help result epilepsy. with are the franchises, in over profile, next rare indication portfolio, along wake, and years, to X patients advancing we sleep programs every development have our made X least product thousands in our at hundreds neurological progress diversifying successful, If multiple stage late in neurobehavioral our development expanding across
thank participating Harmony their trials behalf in patients their our dedication clinical hard and forward updates the clinical to look efforts and clinical program. of at and and On to like Harmony, of as to continue teams development of proud investigators our families I for advance our commitment as would our us well and sharing we work programs. in additional development advance helping the site personnel all as for I'm
to an the our Kapadia, performance. CFO, update Sandip turn on now Sandy? for call I'll over financial our
